IQVIA (NYSE:IQV) Upgraded by Wall Street Zen to Buy Rating

Posted by Stacy Sanders on Aug 2nd, 2026

Wall Street Zen upgraded shares of IQVIA (NYSE:IQV – Free Report) from a hold rating to a buy rating in a research note released on Saturday.

A number of other analysts have also recently issued reports on IQV. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. HSBC restated a “buy” rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. BMO Capital Markets lifted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday. Stifel Nicolaus upped their price objective on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, TD Cowen increased their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

View Our Latest Stock Analysis on IQV

IQVIA Stock Performance

Shares of IQV stock opened at $235.09 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.75. IQVIA has a fifty-two week low of $154.50 and a fifty-two week high of $251.36. The stock’s 50-day moving average is $194.75 and its two-hundred day moving average is $187.20. The firm has a market cap of $38.70 billion, a P/E ratio of 29.17, a PEG ratio of 1.99 and a beta of 1.20.

IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter in the previous year, the business posted $2.81 EPS. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts predict that IQVIA will post 11.61 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in IQV. Tema ETFs LLC grew its holdings in shares of IQVIA by 9.4% during the 2nd quarter. Tema ETFs LLC now owns 3,370 shares of the medical research company’s stock worth $651,000 after purchasing an additional 290 shares in the last quarter. Fulton Bank N.A. raised its stake in shares of IQVIA by 2.9% in the second quarter. Fulton Bank N.A. now owns 6,118 shares of the medical research company’s stock valued at $1,182,000 after purchasing an additional 175 shares in the last quarter. Franklin Street Advisors Inc. NC lifted its position in IQVIA by 1.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 100,198 shares of the medical research company’s stock worth $19,360,000 after purchasing an additional 1,002 shares during the period. HF Advisory Group LLC boosted its stake in IQVIA by 25.7% during the second quarter. HF Advisory Group LLC now owns 9,095 shares of the medical research company’s stock worth $1,757,000 after buying an additional 1,861 shares in the last quarter. Finally, Oliver Luxxe Assets LLC acquired a new stake in IQVIA during the second quarter worth $3,589,000. 89.62% of the stock is currently owned by institutional investors.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

About IQVIA

(Get Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.